Drug Companies Fear Brexit Will Hit Medicine Trade

Time is running short for a Brexit agreement that will allow the free movement of medicines through the U.K. and the rest of the European Union.

A myriad of issues, including guidance on transferring product registration and drug testing in the region, are yet to be resolved, Alan Morrison, vice president of regulatory affairs international for Merck & Co., said in an interview in London. The problem is particularly acute for drug and biotech companies whose products sometimes take years to make, test and navigate through regulatory channels.

“Will we be able to do everything on time? Probably not,” Morrison said.

Source link